Chamberlain University | NR 567 Advanced Pharmacology for the AGACNP
NR 567 Advanced Pharmacology for the AGACNP
Final Examination 2026/2027 | Verified Questions
Chamberlain University | Advanced Pharmacology for the AGACNP | Professional Nurse Practitioner Candidates
150 Verified Questions | 6 Core Domains | Academic Year 2026/2027
Prepared by
Chamberlain University | NR 567 Advanced Pharmacology for the AGACNP
Final Examination Actual Exam | Academic Year 2026/2027
NR 567 Advanced Pharmacology for the AGACNP Final Examination 2026/2027 | Verified Questions
,INTRODUCTION
This document contains 150 original verified questions covering the full NR 567 Final Examination. The questions
are organized across six core domains: Pharmacokinetics, Pharmacodynamics & Receptor Pharmacology;
Cardiovascular & Hematologic Pharmacology; Neurologic & Psychiatric Pharmacology; Endocrine & Metabolic
Pharmacology; Critical Care, Sedation & Pain Management; and Anti-Infective & Special Populations
Pharmacology. Each question is designed to reinforce the official NR 567 Final Examination course objectives for
actual exam readiness and advanced pharmacologic proficiency, aligned to the 2026/2027 academic year. Content
is original and constructed to support clinical judgment, evidence-based pharmacologic decision-making, and
professional nurse practitioner standards consistent with Chamberlain University guidelines, the AANPCB
AGACNP Content Outline, the NCSBN Clinical Judgment Measurement Model, and foundational advanced
pharmacology methodology.
ACTUAL QUESTIONS
Domain 1: Pharmacokinetics, Pharmacodynamics & Receptor Pharmacology
Question 1. A drug that follows zero-order kinetics at therapeutic concentrations will exhibit
which characteristic when the dose is increased?
A. Proportional increase in steady-state concentration.
B. Disproportionate and potentially toxic rise in plasma concentration once metabolizing enzymes are
saturated.
C. No change in plasma concentration.
D. Faster clearance with higher doses.
Correct Answer: D
Rationale: Zero-order (capacity-limited) kinetics, as seen with phenytoin at higher concentrations, means
elimination rate is constant. Once enzymes are saturated, small dose increases produce large, nonlinear rises in
plasma level.
Question 2. Which adrenergic agonist primarily stimulates alpha-1 receptors with minimal beta
activity?
A. Isoproterenol.
B. Phenylephrine.
C. Epinephrine.
D. Dopamine at high doses only.
Correct Answer: A
Rationale: Phenylephrine is a selective alpha-1 agonist used for vasoconstriction. Isoproterenol is pure beta;
epinephrine stimulates alpha and beta; dopamine has dose-dependent receptor activity.
Question 3. Norepinephrine’s receptor activity profile is best described as:
A. Beta-1 and beta-2 only.
B. Alpha-1, alpha-2, and beta-1.
C. Alpha-1 only.
D. Dopamine receptors exclusively.
Correct Answer: D
Rationale: Norepinephrine primarily activates alpha-1, alpha-2, and beta-1 receptors, producing
vasoconstriction and positive inotropy/chronotropy with less beta-2 effect than epinephrine.
Question 4. A drug with extensive hepatic first-pass metabolism will have higher bioavailability
when administered by which route?
A. Oral tablet.
B. Sublingual or intravenous route that bypasses the portal circulation.
C. Rectal administration exclusively.
D. Intramuscular injection into a poorly perfused site.
NR 567 Advanced Pharmacology for the AGACNP Final Examination 2026/2027 | Verified Questions
,Correct Answer: B
Rationale: Sublingual and intravenous routes avoid first-pass hepatic extraction, preserving bioavailability for
drugs extensively metabolized by the liver (e.g., nitroglycerin sublingual).
Question 5. Steady-state plasma concentration for a drug with a half-life of approximately 36
hours is typically reached after how many days of continuous dosing?
A. 1 day.
B. Approximately 7 days (4–5 half-lives).
C. 24 hours regardless of half-life.
D. Immediately after the loading dose only.
Correct Answer: D
Rationale: Steady state is generally achieved after 4–5 half-lives. For digoxin (t½ ≈ 36 h), this corresponds to
roughly one week of maintenance dosing.
Question 6. Alpha-1 receptor activation produces which primary vascular effect?
A. Vasodilation of arteries and veins.
B. Vasoconstriction of arteries and veins with elevation of blood pressure.
C. Decreased heart rate.
D. Bronchodilation.
Correct Answer: B
Rationale: Alpha-1 stimulation causes vasoconstriction of both resistance and capacitance vessels, raising
systemic vascular resistance and blood pressure.
Question 7. Alpha-2 receptor agonists in the central nervous system primarily:
A. Increase sympathetic outflow.
B. Decrease sympathetic outflow and can provide analgesia.
C. Stimulate beta-1 receptors in the heart.
D. Block muscarinic receptors.
Correct Answer: A
Rationale: Central alpha-2 activation inhibits sympathetic outflow (e.g., clonidine) and contributes to analgesic
effects (e.g., dexmedetomidine).
Question 8. Beta-1 receptor stimulation results in:
A. Bronchodilation and uterine relaxation.
B. Increased heart rate, force of contraction, and cardiac output.
C. Vasoconstriction of skeletal-muscle arterioles.
D. Decreased renin release.
Correct Answer: C
Rationale: Beta-1 receptors in the heart mediate positive chronotropic and inotropic effects, increasing cardiac
output and supporting tissue perfusion.
Question 9. A competitive antagonist shifts the agonist dose–response curve in which direction?
A. Downward without changing potency.
B. Rightward, decreasing apparent potency while preserving maximal efficacy if sufficient agonist is present.
C. Leftward, increasing potency.
D. Completely abolishes the response at all agonist concentrations.
Correct Answer: A
Rationale: Competitive antagonists increase the apparent EC50 (right shift) but can be overcome by higher
agonist concentrations, preserving Emax.
Question 10. Which parameter best describes the fraction of an administered dose that reaches
systemic circulation unchanged?
NR 567 Advanced Pharmacology for the AGACNP Final Examination 2026/2027 | Verified Questions
, A. Clearance.
B. Volume of distribution.
C. Bioavailability (F).
D. Elimination half-life.
Correct Answer: B
Rationale: Bioavailability quantifies the extent of systemic exposure relative to the administered dose and is
reduced by incomplete absorption or first-pass metabolism.
Question 11. A drug with a large volume of distribution (Vd) is most likely to:
A. Remain confined to plasma.
B. Distribute extensively into tissues, often requiring a larger loading dose to achieve target plasma
concentration.
C. Be eliminated solely by glomerular filtration.
D. Have negligible tissue binding.
Correct Answer: C
Rationale: Large Vd indicates extensive tissue distribution. Loading doses are calculated as target
concentration × Vd to rapidly achieve desired levels.
Question 12. Oxybutynin’s primary mechanism on the bladder involves:
A. Stimulation of beta-3 receptors to relax the detrusor.
B. Antagonism of M3 muscarinic receptors on the detrusor, reducing involuntary contractions and urgency.
C. Inhibition of acetylcholine release at the neuromuscular junction.
D. Agonism at nicotinic receptors.
Correct Answer: A
Rationale: Oxybutynin is an antimuscarinic that blocks M3 receptors on bladder smooth muscle, decreasing
detrusor overactivity and the urge to void.
Question 13. Therapeutic drug monitoring is most useful for drugs that exhibit:
A. Wide therapeutic index and predictable kinetics.
B. Narrow therapeutic index, significant interpatient variability, or concentration-related toxicity.
C. No relationship between plasma level and effect.
D. Only intravenous administration.
Correct Answer: B
Rationale: Drugs such as digoxin, phenytoin, lithium, and aminoglycosides benefit from TDM because of
narrow margins between efficacy and toxicity.
Question 14. A noncompetitive antagonist typically:
A. Shifts the agonist curve rightward without changing maximal response.
B. Reduces the maximal response (Emax) of the agonist and cannot be fully overcome by increasing agonist
concentration.
C. Increases the potency of the agonist.
D. Has no effect on the dose–response curve.
Correct Answer: C
Rationale: Noncompetitive (or irreversible) antagonism lowers the ceiling response; additional agonist cannot
restore the original Emax.
Question 15. Which factor most directly determines the time required to reach steady state during
continuous infusion or repeated dosing?
A. The loading dose size.
B. The elimination half-life of the drug.
C. The volume of the infusion bag.
D. The route of administration alone.
NR 567 Advanced Pharmacology for the AGACNP Final Examination 2026/2027 | Verified Questions
NR 567 Advanced Pharmacology for the AGACNP
Final Examination 2026/2027 | Verified Questions
Chamberlain University | Advanced Pharmacology for the AGACNP | Professional Nurse Practitioner Candidates
150 Verified Questions | 6 Core Domains | Academic Year 2026/2027
Prepared by
Chamberlain University | NR 567 Advanced Pharmacology for the AGACNP
Final Examination Actual Exam | Academic Year 2026/2027
NR 567 Advanced Pharmacology for the AGACNP Final Examination 2026/2027 | Verified Questions
,INTRODUCTION
This document contains 150 original verified questions covering the full NR 567 Final Examination. The questions
are organized across six core domains: Pharmacokinetics, Pharmacodynamics & Receptor Pharmacology;
Cardiovascular & Hematologic Pharmacology; Neurologic & Psychiatric Pharmacology; Endocrine & Metabolic
Pharmacology; Critical Care, Sedation & Pain Management; and Anti-Infective & Special Populations
Pharmacology. Each question is designed to reinforce the official NR 567 Final Examination course objectives for
actual exam readiness and advanced pharmacologic proficiency, aligned to the 2026/2027 academic year. Content
is original and constructed to support clinical judgment, evidence-based pharmacologic decision-making, and
professional nurse practitioner standards consistent with Chamberlain University guidelines, the AANPCB
AGACNP Content Outline, the NCSBN Clinical Judgment Measurement Model, and foundational advanced
pharmacology methodology.
ACTUAL QUESTIONS
Domain 1: Pharmacokinetics, Pharmacodynamics & Receptor Pharmacology
Question 1. A drug that follows zero-order kinetics at therapeutic concentrations will exhibit
which characteristic when the dose is increased?
A. Proportional increase in steady-state concentration.
B. Disproportionate and potentially toxic rise in plasma concentration once metabolizing enzymes are
saturated.
C. No change in plasma concentration.
D. Faster clearance with higher doses.
Correct Answer: D
Rationale: Zero-order (capacity-limited) kinetics, as seen with phenytoin at higher concentrations, means
elimination rate is constant. Once enzymes are saturated, small dose increases produce large, nonlinear rises in
plasma level.
Question 2. Which adrenergic agonist primarily stimulates alpha-1 receptors with minimal beta
activity?
A. Isoproterenol.
B. Phenylephrine.
C. Epinephrine.
D. Dopamine at high doses only.
Correct Answer: A
Rationale: Phenylephrine is a selective alpha-1 agonist used for vasoconstriction. Isoproterenol is pure beta;
epinephrine stimulates alpha and beta; dopamine has dose-dependent receptor activity.
Question 3. Norepinephrine’s receptor activity profile is best described as:
A. Beta-1 and beta-2 only.
B. Alpha-1, alpha-2, and beta-1.
C. Alpha-1 only.
D. Dopamine receptors exclusively.
Correct Answer: D
Rationale: Norepinephrine primarily activates alpha-1, alpha-2, and beta-1 receptors, producing
vasoconstriction and positive inotropy/chronotropy with less beta-2 effect than epinephrine.
Question 4. A drug with extensive hepatic first-pass metabolism will have higher bioavailability
when administered by which route?
A. Oral tablet.
B. Sublingual or intravenous route that bypasses the portal circulation.
C. Rectal administration exclusively.
D. Intramuscular injection into a poorly perfused site.
NR 567 Advanced Pharmacology for the AGACNP Final Examination 2026/2027 | Verified Questions
,Correct Answer: B
Rationale: Sublingual and intravenous routes avoid first-pass hepatic extraction, preserving bioavailability for
drugs extensively metabolized by the liver (e.g., nitroglycerin sublingual).
Question 5. Steady-state plasma concentration for a drug with a half-life of approximately 36
hours is typically reached after how many days of continuous dosing?
A. 1 day.
B. Approximately 7 days (4–5 half-lives).
C. 24 hours regardless of half-life.
D. Immediately after the loading dose only.
Correct Answer: D
Rationale: Steady state is generally achieved after 4–5 half-lives. For digoxin (t½ ≈ 36 h), this corresponds to
roughly one week of maintenance dosing.
Question 6. Alpha-1 receptor activation produces which primary vascular effect?
A. Vasodilation of arteries and veins.
B. Vasoconstriction of arteries and veins with elevation of blood pressure.
C. Decreased heart rate.
D. Bronchodilation.
Correct Answer: B
Rationale: Alpha-1 stimulation causes vasoconstriction of both resistance and capacitance vessels, raising
systemic vascular resistance and blood pressure.
Question 7. Alpha-2 receptor agonists in the central nervous system primarily:
A. Increase sympathetic outflow.
B. Decrease sympathetic outflow and can provide analgesia.
C. Stimulate beta-1 receptors in the heart.
D. Block muscarinic receptors.
Correct Answer: A
Rationale: Central alpha-2 activation inhibits sympathetic outflow (e.g., clonidine) and contributes to analgesic
effects (e.g., dexmedetomidine).
Question 8. Beta-1 receptor stimulation results in:
A. Bronchodilation and uterine relaxation.
B. Increased heart rate, force of contraction, and cardiac output.
C. Vasoconstriction of skeletal-muscle arterioles.
D. Decreased renin release.
Correct Answer: C
Rationale: Beta-1 receptors in the heart mediate positive chronotropic and inotropic effects, increasing cardiac
output and supporting tissue perfusion.
Question 9. A competitive antagonist shifts the agonist dose–response curve in which direction?
A. Downward without changing potency.
B. Rightward, decreasing apparent potency while preserving maximal efficacy if sufficient agonist is present.
C. Leftward, increasing potency.
D. Completely abolishes the response at all agonist concentrations.
Correct Answer: A
Rationale: Competitive antagonists increase the apparent EC50 (right shift) but can be overcome by higher
agonist concentrations, preserving Emax.
Question 10. Which parameter best describes the fraction of an administered dose that reaches
systemic circulation unchanged?
NR 567 Advanced Pharmacology for the AGACNP Final Examination 2026/2027 | Verified Questions
, A. Clearance.
B. Volume of distribution.
C. Bioavailability (F).
D. Elimination half-life.
Correct Answer: B
Rationale: Bioavailability quantifies the extent of systemic exposure relative to the administered dose and is
reduced by incomplete absorption or first-pass metabolism.
Question 11. A drug with a large volume of distribution (Vd) is most likely to:
A. Remain confined to plasma.
B. Distribute extensively into tissues, often requiring a larger loading dose to achieve target plasma
concentration.
C. Be eliminated solely by glomerular filtration.
D. Have negligible tissue binding.
Correct Answer: C
Rationale: Large Vd indicates extensive tissue distribution. Loading doses are calculated as target
concentration × Vd to rapidly achieve desired levels.
Question 12. Oxybutynin’s primary mechanism on the bladder involves:
A. Stimulation of beta-3 receptors to relax the detrusor.
B. Antagonism of M3 muscarinic receptors on the detrusor, reducing involuntary contractions and urgency.
C. Inhibition of acetylcholine release at the neuromuscular junction.
D. Agonism at nicotinic receptors.
Correct Answer: A
Rationale: Oxybutynin is an antimuscarinic that blocks M3 receptors on bladder smooth muscle, decreasing
detrusor overactivity and the urge to void.
Question 13. Therapeutic drug monitoring is most useful for drugs that exhibit:
A. Wide therapeutic index and predictable kinetics.
B. Narrow therapeutic index, significant interpatient variability, or concentration-related toxicity.
C. No relationship between plasma level and effect.
D. Only intravenous administration.
Correct Answer: B
Rationale: Drugs such as digoxin, phenytoin, lithium, and aminoglycosides benefit from TDM because of
narrow margins between efficacy and toxicity.
Question 14. A noncompetitive antagonist typically:
A. Shifts the agonist curve rightward without changing maximal response.
B. Reduces the maximal response (Emax) of the agonist and cannot be fully overcome by increasing agonist
concentration.
C. Increases the potency of the agonist.
D. Has no effect on the dose–response curve.
Correct Answer: C
Rationale: Noncompetitive (or irreversible) antagonism lowers the ceiling response; additional agonist cannot
restore the original Emax.
Question 15. Which factor most directly determines the time required to reach steady state during
continuous infusion or repeated dosing?
A. The loading dose size.
B. The elimination half-life of the drug.
C. The volume of the infusion bag.
D. The route of administration alone.
NR 567 Advanced Pharmacology for the AGACNP Final Examination 2026/2027 | Verified Questions
